Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Chuikyo Summarizes Discussions on Revision of Medical Fees
October 13, 2003
-
ARCHIVE Korosho WG to Screen OTC Drugs for Sales Deregulation
October 13, 2003
-
ARCHIVE Insurance Coverage Expected Soon for M-VAC Therapy
October 13, 2003
-
ARCHIVE 10 Suspected Deaths Due to OTC Drugs Since FY2001: Korosho
October 13, 2003
-
ARCHIVE Korosho Approves Azwell-Fukujin's Business Rebuilding Plan
October 13, 2003
-
ARCHIVE BULLETIN
October 13, 2003
-
ARCHIVE REGULATORY NEWS IN BRIEF
October 13, 2003
-
ARCHIVE WORLD NEWS IN BRIEF
October 13, 2003
-
ARCHIVE Medical Members Submit Petition on Medical Fee Revision at Chuikyo
October 13, 2003
-
ARCHIVE To Ensure Bilateral Communication between Banyu, Merck: Mr Hirate
October 13, 2003
-
ARCHIVE Full Bungyo to Increase Medical Costs by \1.7 Tril.: Report
October 13, 2003
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 13, 2003
-
ARCHIVE Mr Butler Explains PhRMA Report on Value of New Medicines
October 13, 2003
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
October 13, 2003
-
ARCHIVE Sugi Yakkyoku: Strong Growth in 1st-half Sales, Profits
October 13, 2003
-
ARCHIVE PRESS SEMINAR
October 13, 2003
-
ARCHIVE Asahi Kasei Pharma Aims for Sales of \160 Bil. in FY2008
October 13, 2003
-
ARCHIVE NEW PRODUCTS
October 13, 2003
-
ARCHIVE Novartis Pharma Begins to Independently Market Zaditen
October 13, 2003
-
ARCHIVE Simvastatin Useful in Patients with Diabetic Complications
October 13, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…